Table 2.
Demographics and Baseline Clinical and Disease Characteristics of Patients Enrolled in the Brave Dreams Trial.a
| Variable | Angioplasty (n=86) | Sham (n=44) |
|---|---|---|
| Age, y | 41.0±10.6 | 37.8±10.3 |
| Women | 50 (58.1) | 31 (70.5) |
| EDSS score | ||
| 2 or 2.5 | 51 (59.3) | 24 (54.5) |
| 3 or 3.5 | 22 (25.6) | 12 (27.3) |
| 4 or 4.5 | 10 (11.6) | 3 (6.8) |
| 5 or 5.5 | 3 (3.5) | 5 (11.4) |
| Duration of MS in relapsing/remitting patients, y | 4.3 (2.8, 8.4) | 6.1 (3.7, 9) |
| Duration of MS in secondary/progressive patients, y | 7.9 (4.7, 11.8) | 8 (7.6, 9) |
| Months from progression | 37.5 (22, 53) | 38 (26, 44) |
| Relapses in previous 2 years | ||
| 0 | 10 (11.6) | 5 (11.4) |
| 1 | 44 (51.2) | 26 (59.1) |
| 2 | 24 (27.9) | 4 (9.1) |
| ≥3 | 8 (9.3) | 9 (20.4) |
| Intraluminal obstacle at ECD in at least 1 IJV | 80 (93.0) | 42 (95.4) |
| Bidirectional and/or absent flow at ECD in at least 1 IJV in 2 positions | 82 (95.3) | 43 (97.7) |
| Patients with gadolinium-enhancing T1 lesions | 18 (20.9) | 7 (15.9) |
| Immunomodulatory therapy | 35 (41.0) | 24 (54.6) |
Abbreviations: ECD, echo-Doppler; EDSS, Expanded Disability Status Scale; IJV, internal jugular vein; MS, multiple sclerosis.
a
Continuous data are presented as the mean ± standard deviation or median (interquartile range Q1, Q3); categorical data are given as the number (percentage).